Methadone

• Opioid Use Disorder
• Chronic Pain Management
• Opioid Withdrawal

Methadone (Dolophine, Methadose) is a long-acting synthetic opioid used in two distinct contexts: medication for opioid use disorder (OUD) dispensed through certified opioid treatment programs, and management of severe chronic pain requiring around-the-clock opioid therapy. Because of its long, variable half-life and unique cardiac risk profile, it requires careful initiation, slow titration, and ongoing oversight that distinguish it from every other opioid in routine use.

Mechanism of Action

Methadone is a full mu-opioid receptor agonist with additional pharmacology that distinguishes it from other opioids. It also acts as an NMDA receptor antagonist, which may contribute to analgesic effect in neuropathic pain and may attenuate the development of opioid tolerance. It weakly inhibits serotonin and norepinephrine reuptake, which is one reason serotonin syndrome can occur when methadone is combined with serotonergic agents such as SSRIs, SNRIs, or tramadol. Critically, methadone blocks the hERG potassium channel — the source of its dose-dependent QT-prolonging effect and its association with torsades de pointes.

The drug's pharmacokinetics are its defining feature. Plasma half-life ranges widely from 8 to 59 hours (mean ~24 hours), but analgesic duration is much shorter (4–8 hours). This decoupling means that, when used for pain, the drug must be dosed every 8 hours for analgesia even though plasma levels accumulate over 4–7 days to reach steady state. Underestimating accumulation is the most common cause of fatal methadone overdose during titration — patients may feel fine on day 2 and apneic on day 5 from the same dose. Methadone is metabolized primarily by CYP3A4 and CYP2B6, with substantial inter-patient variability that further complicates dosing. Genetic polymorphisms in CYP enzymes contribute to the wide spread of plasma levels seen in patients receiving identical doses.

Methadone is highly protein-bound and lipophilic, with extensive tissue distribution that creates a deep peripheral compartment from which the drug slowly redistributes back into plasma. This pharmacokinetic profile underlies both the smooth 24-hour coverage that makes methadone effective in OUD and the unpredictable accumulation that makes it dangerous if titrated too quickly.

Clinical Use

For opioid use disorder, methadone is a first-line maintenance agent, supported by decades of evidence demonstrating reduced illicit opioid use, reduced overall mortality, reduced HIV and hepatitis C transmission, and improved social functioning. Federal regulations permit dispensing for OUD only through SAMHSA-certified opioid treatment programs (commonly called methadone clinics). Buprenorphine and buprenorphine-naloxone can be prescribed in office-based primary care settings under the Mainstreaming Addiction Treatment Act, making them often the more accessible first option for many patients. Naltrexone is a non-opioid alternative for selected patients who can tolerate withdrawal before initiation. Choice between these agents depends on patient preference, severity of opioid use disorder, comorbidities, prior treatment history, and access. Patients with very high opioid tolerance, prior buprenorphine failure, or strong patient preference often do best on methadone.

For chronic pain, methadone is generally reserved for patients with severe pain inadequately controlled on other long-acting opioids, particularly when neuropathic features are prominent or when cost is a barrier (methadone is inexpensive). It is not a first-line choice and the CDC explicitly cautions that prescribing methadone for pain requires more familiarity than prescribing other opioids. Alternatives for chronic pain include morphine, oxycodone, fentanyl, hydrocodone-acetaminophen, tramadol, and the gabapentinoids gabapentin and pregabalin for neuropathic pain. Non-opioid analgesics including acetaminophen, NSAIDs such as ibuprofen, naproxen, meloxicam, celecoxib, and diclofenac, and adjuncts like duloxetine, venlafaxine, or topical lidocaine should be optimized first. The SAMHSA methadone resource and CDC clinical practice guideline for prescribing opioids for pain are essential references.

How to Take It

For opioid use disorder, doses are dispensed daily under direct observation at the OTP during induction; take-home privileges are earned over time as stability is demonstrated through clean urine drug screens, attendance, and clinical progress. Patients should never share, divert, or stockpile doses — pediatric ingestion of even one tablet has caused fatal overdose, and accidental adult ingestion at non-tolerant doses is similarly lethal. Take-home medication must be stored in a locked container.

For pain, the drug is taken on a fixed schedule — typically every 8 hours — rather than as needed. During the first 1–2 weeks, patients should avoid alcohol entirely, avoid driving until they understand how the drug affects them, and have a household member trained in naloxone administration with rescue spray on hand and visible. Naloxone should be co-prescribed with any methadone prescription as a matter of routine. Patients and families should know how to recognize an opioid overdose: pinpoint pupils, slow or absent breathing, blue lips or fingertips, and unresponsiveness to voice or sternal rub.

Never combine methadone with benzodiazepines such as alprazolam, lorazepam, clonazepam, or diazepam without explicit physician guidance — the combination dramatically raises overdose mortality. Sleep aids such as zolpidem, trazodone, lemborexant, or suvorexant; muscle relaxants like cyclobenzaprine or methocarbamol; and gabapentinoids all add respiratory-depressant risk and should be coordinated with the prescriber. Even over-the-counter sleep aids and antihistamines deserve discussion. Constipation is nearly universal on methadone and should be managed proactively with hydration, fiber, and a stimulant laxative or osmotic agent like polyethylene glycol.

Monitoring and Follow-Up

A baseline 12-lead ECG is recommended before initiation, with a repeat at 30 days and annually thereafter — and any time the dose exceeds 100 mg/day or other QT-prolonging drugs are added. A QTc above 500 ms warrants risk-benefit reassessment and possible dose reduction or discontinuation. Routine labs include LFTs, serum electrolytes (low potassium and magnesium worsen QT risk), and pregnancy testing where applicable. Hepatitis C and HIV screening are appropriate in OUD populations because of the historical association with injection drug use, and treatment with agents such as sofosbuvir-velpatasvir or glecaprevir-pibrentasvir for HCV and antiretrovirals like bictegravir-emtricitabine-tenofovir or dolutegravir plus tenofovir-emtricitabine for HIV is now routine. The understanding blood work article covers what these labs show and why each matters.

For patients managing pain, our guide to managing chronic pain without opioids provides context on multimodal approaches — physical therapy, behavioral interventions, non-opioid pharmacotherapy — that can reduce opioid burden over time. Periodic state prescription drug monitoring program (PDMP) checks and urine drug testing are standard for any patient on chronic opioid therapy. The article on how to talk to your doctor helps patients raise sensitive topics like effectiveness, side effects, or wanting to taper. Mental health comorbidity is common in both OUD and chronic pain populations, and screening for depression and anxiety should be routine.

Special Populations

Methadone is the standard of care for pregnant patients with opioid use disorder (alongside buprenorphine); the alternative — untreated addiction — carries far greater fetal risk than the medication itself. Neonatal opioid withdrawal syndrome is expected and is managed in the hospital with supportive care and sometimes adjunct medication. Methadone is excreted in breast milk in low quantities, and breastfeeding is generally encouraged because it reduces neonatal abstinence severity and supports maternal-infant bonding.

Elderly patients require lower starting doses and slower titration because of pharmacokinetic changes and increased sensitivity to respiratory depression, sedation, and falls. Hepatic impairment reduces clearance unpredictably; renal impairment requires caution but no specific dose adjustment because the kidney is a minor elimination route. Pediatric use is restricted to specialized centers. Patients with sleep apnea face elevated overdose risk and should generally avoid methadone or use it only with rigorous CPAP compliance and close monitoring.

When to Contact Your Doctor

Call 911 and use naloxone for: extreme drowsiness, slow or irregular breathing, blue lips, or unresponsiveness. Contact the prescriber promptly for: palpitations, lightheadedness, or syncope (possible arrhythmia); persistent constipation despite stool softeners or polyethylene glycol; new chronic swelling of legs or face; or any plan to start a new medication — especially benzodiazepines, antibiotics like clarithromycin, erythromycin, or ciprofloxacin, or antifungals such as fluconazole. Major CYP3A4 inducers like rifampin, carbamazepine, and phenytoin reduce methadone levels and may precipitate withdrawal. The FDA Drug Safety and Availability page maintains current warnings and the MedlinePlus methadone page provides patient-facing detail.

If you have questions about methadone or your treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.